DanCann Pharma Yönetim

Yönetim kriter kontrolleri 2/4

DanCann Pharma CEO'su Jeppe Rasmussen, Jan2018 tarihinde atandı, in görev süresi 6.83 yıldır. şirketin hisselerinin 0.23% doğrudan sahiptir ve bu hisselerin değeri DKK 19.60K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 3.6 yıldır.

Anahtar bilgiler

Jeppe Rasmussen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jeppe Rasmussen (29 yo)

6.8yrs

Görev süresi

Mr. Jeppe Krog Rasmussen has been Director of Dancann Pharma A/S since September 20, 2022. He Founded and serves as Chief Executive Officer of Dancann Pharma A/S since 2018 and serves as its Member of Exec...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeppe Rasmussen	Founder	6.8yrs	Veri yok	0.23% DKK 19.6k
Peter Sondergaard	Chief Financial Officer	1.8yrs	Veri yok	Veri yok
Jens Markussen	Head of Production	3.7yrs	Veri yok	Veri yok
John Frellsen	Chief Commercial Officer	4.8yrs	Veri yok	Veri yok
Charlotte Jorgensen	Head of Quality Assurance	2.3yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: DANCAN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeppe Rasmussen	Founder	2.2yrs	Veri yok	0.23% DKK 19.6k
Carsten Trads	Chairman of the Board	4.8yrs	Veri yok	0.027% DKK 2.3k
Christian Carlsen	Vice-Chairman	3.6yrs	Veri yok	0.016% DKK 1.4k

3.6yrs

Ortalama Görev Süresi

40yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DANCAN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

DanCann Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

DanCann Pharma A/S, Annual General Meeting, May 30, 2024

Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member

DanCann Pharma A/S Appoints Peter Søndergaard as CFO

DanCann Pharma A/S Announces Board of Directors Appointments

Dancann Pharma A/S Announces Board Changes

Dancann Pharma A/S Appoints Charlotte Hagedorn Jørgensen as New Head of Quality Assurance

Recent updates

DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024

Second quarter 2024 earnings released: kr.0.004 loss per share (vs kr.0.05 loss in 2Q 2023)

DanCann Pharma A/S Revises Earnings Guidance for 2024

DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024

DanCann Pharma A/S Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings released

DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024

DanCann Pharma A/S, Annual General Meeting, May 30, 2024

Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024

Full year 2023 earnings released: kr.0.13 loss per share (vs kr.0.25 loss in FY 2022)

Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025

Third quarter 2023 earnings released: kr.0.033 loss per share (vs kr.0.096 loss in 3Q 2022)

Second quarter 2023 earnings released

New major risk - Share price stability

New major risk - Revenue and earnings growth

Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product Approval

Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member

Full year 2022 earnings: Revenues miss analyst expectations

Dancann Pharma A/S to Report Fiscal Year 2022 Results on Feb 27, 2023

DanCann Pharma A/S Appoints Peter Søndergaard as CFO

DanCann Pharma A/S Receives EU-GMP Certification for Its Manufacturing Facility Biotech Pharm1

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released

Dancann Pharma A/S to Report Q3, 2022 Results on Nov 04, 2022

DanCann Pharma A/S Announces Board of Directors Appointments

Dancann Pharma A/S Announces Board Changes

Second quarter 2022 earnings released

Dancann Pharma A/S Appoints Charlotte Hagedorn Jørgensen as New Head of Quality Assurance

Forecast to breakeven in 2024

Dancann Pharma A/S Appoints Martin Vedel Ernst as New Chief Financial Officer

Dancann Pharma A/S Elects Tue Østergaard as New Board Member

No independent directors

DanCann Pharma A/S Appoints Sarah Mai Lykke-Kjeldsen as New Chief Operating Officer, Effective 1 April 2022

Dancann Pharma A/S to Report Fiscal Year 2021 Results on Apr 13, 2022

Dancann Pharma A/S Has Submitted Application to the Danish Medicines Agency for Eu-GMP-Approval for Biotech Pharm

Forecast to breakeven in 2025

Dancann Pharma A/S Announces Executive Changes

Dancann Pharma A/S Appoints Jens Markussen as Head of Production

DanCann Pharma A/S Signs a Letter of Intent with Canadian Tetra Bio-Pharma Inc. for the Exclusive Distribution of ReduvoT Adversa[®

Dancann Pharma A/S Submits New Application to the Danish Medicine Agency for Authorization to Produce Cannabis Intermediate Products

DanCann Pharma A/S enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia

Dancann Pharma A/S to Report Fiscal Year 2020 Results on Apr 08, 2021

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş